President Trump on Tuesday told a group of drug company executives gathered for a meeting at the White House that they need to “get prices down.”
“You folks have done a tremendous job but we have to get prices down,” Trump said, according to a pool report.
Trump has been a critic of high drug prices, and has endorsed measures like allowing Medicare to negotiate prices.
But the president also called for reducing regulations to allow for faster approvals of new drugs and to allow drug companies to bring jobs back to the US.
“We’re going to be cutting regulation at a level nobody’s ever seen before,” Trump said in the meeting with executives.
“You can’t get approval for the plant and then you can’t get approval to make the drug, other than that you’re doing fantastic,” he said.
Trump called drug prices “astronomical.”
“US drug companies have produced extraordinary results for our country, but the pricing has been astronomical for our country,” he said.
Still, he also offered to make the Food and Drug Administration’s approval of new drugs “much faster.”
Full Content: The Hill
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Appoints Law Firms to Lead Consumer Antitrust Litigation Against Apple
Dec 22, 2024 by
CPI
Epic Health Systems Seeks Dismissal of Antitrust Suit Filed by Particle Health
Dec 22, 2024 by
CPI
Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues
Dec 22, 2024 by
CPI
Google Proposes Revised Revenue-Sharing Limits Amid Antitrust Battle
Dec 22, 2024 by
CPI
Japan’s Antitrust Authority Expected to Sanction Google Over Monopoly Practices
Dec 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand